|
Back to Home » October 2019 News » Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon |
Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon |
October 01, 2019
STOCKHOLM, Oct. 1, 2019 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company's lead compound Nefecon, currently in...
Source URL: https://www.prnewswire.com:443/news-releases/positive-interactions-with-ema-provide-route-to-conditional-marketing-authorization-of-lead-candidate-nefecon-300928379.html
|
|
|
|
